

## CONTENTS

### Special Lecture

- 1079** **There Are No Bad Anticancer Agents, Only Bad Clinical Trial Designs—Twenty-first Richard and Hinda Rosenthal Foundation Award Lecture.** Daniel D. Von Hoff.

### Review Article

- 1087** **New Chemotherapeutic Agents Prolong Survival and Improve Quality of Life in Non-Small Cell Lung Cancer: A Review of the Literature and Future Directions.** Paul A. Bunn, Jr. and Karen Kelly.

### Advances in Brief

- 1101** **Combined Analysis of Studies of the Effects of the Matrix Metalloproteinase Inhibitor Marimastat on Serum Tumor Markers in Advanced Cancer: Selection of a Biologically Active and Tolerable Dose for Longer-term Studies.** John Nemunaitis, Christopher Poole, John Primrose, Alexander Rosemurgy, John Malfetano, Peter Brown, Amy Berrington, Alan Cornish, Kevin Lynch, Henrik Rasmussen, David Kerr, David Cox, and Andrew Millar.
- 1111** **High Raf-1 Kinase Activity Protects Human Tumor Cells against Paclitaxel-induced Cytotoxicity.** Aghdass Rasouli-Nia, Dan Liu, Sherry Perdue, and Richard A. Britten.

### Research Articles

- 1117** **Antibody Responses in Melanoma Patients Immunized with an Anti-Idiotypic Antibody Mimicking Disialoganglioside GD2.** Kenneth A. Foon, Goutam Sen, Laura Hutchins, Oscar L. Kashala, Rathin Baral, Maitrayee Banerjee, Mala Chakraborty, Juanita Garrison, Ralph A. Reisfeld, and Malaya Bhattacharya-Chatterjee.
- 1125** ***In Vivo* Toxicity, Pharmacokinetics, and Anticancer Activity of Genistein Linked to Recombinant Human Epidermal Growth Factor.** Fatih M. Uckun, Rama Krishna Narla, Tamer Zeren, Yuri Yanishevski, Dorothea E. Myers, Barbara Waurzyniak, Onur Ek, Elizabeth Schneider, Yoav Messinger, Lisa M. Chelstrom, Roland Gunther, and William Evans.
- 1135** **Human Tumor Antigen-specific T Lymphocytes and Interleukin-2-activated Natural Killer Cells: Comparisons of Antitumor Effects *in Vitro* and *in Vivo*.** Theresa L. Whiteside, Myung-Whun Sung, Shigeki Nagashima, Kazuaki Chikamatsu, Kazuhiko Okada, and Nikola L. Vujanovic.
- 1147** **Infrequent Expression of p21 Is Related to Altered p53 Protein in Pancreatic Carcinoma.** Yu-Xin Hu, Hiroyuki Watanabe, Koushiro Ohtsubo, Yasushi Yamaguchi, Aiguli Ha, Yoshiharu Motoo, Takashi Okai, and Norio Sawabu.

- 1153** **Oral Topotecan Given Once or Twice Daily for Ten Days: A Phase I Pharmacology Study in Adult Patients with Solid Tumors.** Cees J. H. Gerrits, Howard Burris, Jan H. M. Schellens, John R. Eckardt, Andre S. T. Planting, Maria E. L. van der Burg, Gayle I. Rodriguez, Walter J. Loos, Vera van Beurden, Ian Hudson, Scott Fields, Dan D. Von Hoff, and Jaap Verweij.

- 1159** **Phase I Clinical Trial of Perillyl Alcohol Administered Daily.** Gregory H. Ripple, Michael N. Gould, James A. Stewart, Kendra D. Tutsch, Rhoda Z. Arzooonian, Dona Alberti, Chris Feierabend, Marcia Pomplun, George Wilding, and Howard H. Bailey.

- 1165** **Phase I Clinical and Pharmacological Studies of Benzylacetylouridine, a Uridine Phosphorylase Inhibitor.** Giuseppe Pizzorno, Lorrin Yee, Barbara A. Burtness, John C. Marsh, James W. Darnowski, Ming Yu W. Chu, Shih Hsi Chu, Edward Chu, Janine J. Leffert, Robert E. Handschumacher, and Paul Calabresi.

- 1177** ***In Vivo* Native Cellular Fluorescence and Histological Characteristics of Head and Neck Cancer.** Stimson P. Schantz, Venkataswara Kolli, Howard E. Savage, Guopei Yu, Jatin P. Shah, Daniel E. Harris, Alvin Katz, Robert R. Alfano, and Andrew G. Huvos.

- 1183** **Phase I Trial of Subcutaneous Recombinant Human Interleukin-12 in Patients with Advanced Renal Cell Carcinoma.** Robert J. Motzer, Ashok Rakshit, Lawrence H. Schwartz, Thomas Olencki, Thomas M. Malone, Kate Sandstrom, Rosemary Nadeau, Harsukh Parmar, and Ronald Bukowski.

- 1193** **Phase I Study of Suramin Combined with Doxorubicin in the Treatment of Androgen-independent Prostate Cancer.** Shi-Ming Tu, Lance C. Pagliaro, Marie E. Banks, Robert J. Amato, Randall E. Millikan, Nagla A. Bugazia, Timothy Madden, Robert A. Newman, and Christopher J. Logothetis.

- 1203** **A Two-Part Phase I Trial of High-Dose Interleukin 2 in Combination with Soluble (Chinese Hamster Ovary) Interleukin 1 Receptor.** David F. McDermott, Elizabeth G. Trehu, James W. Mier, Damian Sorce, William Rand, Lucie Ronayne, Kerry Kappler, Marguerite Clancy, Mark Klempner, and Michael B. Atkins.

- 1215** **Quantitative [F-18]Fluorodeoxyglucose Positron Emission Tomography in Pretreatment and Grading of Sarcoma.** Janet F. Eary, Ernest U. Conrad, James D. Bruckner, Andrew Folpe, Karen J. Hunt, David A. Mankoff, and Andrew T. Howlett.

- 1221** **Evaluation of the Balance between Angiogenic and Antiangiogenic Circulating Factors in Patients with Breast and Gastrointestinal Cancers.** Daniele Morelli, Debora Lazzzerini, Sara Cazzaniga, Paolo Squicciarini, Paola Bignami, Jeanette A. M. Maier, Lucia Sfondrini, Sylvie Ménard, Maria I. Colnaghi, and Andrea Balsari.

- 1227** **p53 and Thymidylate Synthase Expression in Untreated Stage II Colon Cancer: Associations with Recurrence, Survival, and Site.** Heinz-Josef Lenz, Kathleen D. Danenberg, Cynthia G. Leichman, Barbara Florentine, Patrick G. Johnston, Susan Groshen, Linyun Zhou, Yi Ping Xiong, Peter V. Danenberg, and Lawrence P. Leichman.

- 1235** Patients with Isolated Trisomy 8 in Acute Myeloid Leukemia Are Not Cured with Cytarabine-based Chemotherapy: Results from Cancer and Leukemia Group B 8461. John C. Byrd, David Lawrence, Diane C. Arthur, Mark J. Pettenati, Ramana Tantravahi, Mazin Qumsiyeh, Judith Stamberg, Frederick R. Davey, Charles A. Schiffer, and Clara D. Bloomfield.
- 1243** p53 Point Mutations and Thymidylate Synthase Messenger RNA Levels in Disseminated Colorectal Cancer: An Analysis of Response and Survival. Heinz-Josef Lenz, Kazuhiko Hayashi, Dennis Salonga, Kathleen D. Danenberg, Peter V. Danenberg, Ralf Metzger, Debabrata Banerjee, Joseph R. Bertino, Susan Groshen, Lawrence P. Leichman, and Cynthia G. Leichman.
- 1251** Loss of p21<sup>WAF1/Cip1</sup> Protein Expression Accompanies Progression of Sporadic Colorectal Neoplasms but not Hereditary Nonpolyposis Colorectal Cancers. Frank A. Sinicrope, Gardiner Roddey, Michael Lemoine, Sanbao Ruan, L. Clifton Stephens, Marsha L. Frazier, Yu Shen, and Wei Zhang.
- 1263** Heat Shock Proteins hsp27 and hsp70: Lack of Correlation with Response to Tamoxifen and Clinical Course of Disease in Estrogen Receptor-positive Metastatic Breast Cancer (A Southwest Oncology Group Study). Daniel R. Ciocca, Stephanie Green, Richard M. Elledge, Gary M. Clark, Reginald Pugh, Peter Ravdin, Danika Lew, Silvana Martino, and C. Kent Osborne.
- 1267** Biomarker Study of Primary Nonmetastatic versus Metastatic Invasive Bladder Cancer. Pilar Lianes, Elizabeth Charytonowicz, Carlos Cordon-Cardo, Yves Fradet, H. Barton Grossman, George P. Hemstreet, Frederic M. Waldman, Karen Chew, Leon L. Wheeler, David Faraggi, and the National Cancer Institute Bladder Tumor Marker Network.
- 1273** A Similar Pattern of Chromosomal Alterations in Prostate Cancers from African-Americans and Caucasian Americans. Michael L. Cher, Paul E. Lewis, Mousumi Banerjee, Patrick M. Hurley, Wael Sakr, David J. Grignon, and Isaac J. Powell.
- 1279** Preoperative Serum Vascular Endothelial Growth Factor Can Predict Stage in Colorectal Cancer. Harish Kumar, Kamal Heer, Peter W. R. Lee, Graeme S. Duthie, Alastair W. MacDonald, John Greenman, Michael J. Kerin, and John R. T. Monson.
- 1287** Differential Quantitative Effects of Interleukin (IL)-2 and IL-15 on Cytotoxic Activity and Proliferation by Lymphocytes from Patients Receiving *in Vivo* IL-2 Therapy. Jill L. O. de Jong, Nancy L. Farmer, Bradley R. Javorsky, Mary J. Lindstrom, Jacquelyn A. Hank, and Paul M. Sondel.
- 1297** Effect of Immunosuppressive Agents on the Immunogenicity and Efficacy of an Immunotoxin in Mice. Elysa E. Gelber and Ellen S. Vitetta.
- 1305** Bryostatin 1 Down-Regulates *mdr1* and Potentiates Vincristine Cytotoxicity in Diffuse Large Cell Lymphoma Xenografts. Ayad M. Al-Katib, Mitchell R. Smith, William S. Kamanda, George R. Pettit, Mohammed Hamdan, Anwar N. Mohamed, Bhadrani Chelladurai, and Ramzi M. Mohammad.
- 1315** Restoration of Wild-Type p53 Activity in p53-null HL-60 Cells Confers Multidrug Sensitivity. Jing-Fang Ju, Debabrata Banerjee, Heinz-Josef Lenz, Kathleen D. Danenberg, Thomas C. Schmittgen, C. Paul Spears, Axel H. Schönthal, David J. Manno, Daniel Hochhauser, Joseph R. Bertino, and Peter V. Danenberg.
- 1323** Schedule-dependent Synergism between Raltitrexed and Irinotecan in Human Colon Cancer Cells *in Vitro*. Carlo Aschele, Chiara Baldo, Alberto F. Sobrero, Domizia Debernardis, William G. Bornmann, and Joseph R. Bertino.
- 1331** Antiangiogenic Chemotherapeutic Agents: Characterization in Comparison to Their Tumor Growth Inhibition in Human Renal Cell Carcinoma Models. Michael Schirmer, Jens Hoffmann, Andreas Menrad, and Martin R. Schneider.
- 1337** Successful Treatment of Human Chronic Lymphocytic Leukemia Xenografts with Combination Biological Agents Auristatin PE and Bryostatin I. Ramzi M. Mohammad, Mary L. Varterasian, Victor P. Almachy, Ghadeer N. Hannoudi, George R. Pettit, and Ayad Al-Katib.
- 1345** Higher Potency of *N*-(4-Hydroxyphenyl)retinamide than all-*trans*-Retinoic Acid in Induction of Apoptosis in Non-Small Cell Lung Cancer Cell Lines. Chang-Ping Zou, Jonathan M. Kurie, Dafna Lotan, Chang-Chun Zou, Waun Ki Hong, and Reuben Lotan.
- 
- 1357** **AACR Bulletin Board**  
 Institution of Page Charges  
 1999 Annual Meeting  
 Call for Nominations for 1999 AACR-Pezcoller International Award for Cancer Research  
 Call for Nominations for AACR Awards  
 AACR Special Conferences in Cancer Research
- 1358** **Author Index**
- i** **Instructions for Authors**

# Clinical Cancer Research

## 4 (5)

*Clin Cancer Res* 1998;4:1079-1355.

**Updated version** Access the most recent version of this article at:  
<http://clincancerres.aacrjournals.org/content/4/5.citation>

**E-mail alerts** [Sign up to receive free email-alerts](#) related to this article or journal.

**Reprints and Subscriptions** To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at [pubs@aacr.org](mailto:pubs@aacr.org).

**Permissions** To request permission to re-use all or part of this article, use this link <http://clincancerres.aacrjournals.org/content/4/5.citation>. Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.